Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
15/07/2026 02:18
BRIEF-Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical July 15 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:
H1 2026 NET PROFIT SEEN AT RMB 73-83 MILLION FOR TIANJIN LISHENG PHARMACEUTICAL
Further company coverage: 002393.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tianjin Development Holdings
See all newsHong Kong's Tianjin Development HY revenue on lower pharmaceutical, utilities sales
Brief: Tianjin Development Says Teng Fei Resigns As Chairman And Executive Director
Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
Brief: Tianjin Development Says Tianjin Lisheng Pharmaceutical QTRLY Operating Income RMB 332.28 Mln